CR665
CR665 is a peripheral kappa-opioid receptor agonist that is currently under development for the treatment of pain, inflammation, and pruritus (itching). It is being developed by Cara Therapeutics, a biopharmaceutical company based in the United States.
History[edit | edit source]
CR665 was first synthesized by Cara Therapeutics in the early 2000s as part of their research into peripheral kappa-opioid receptor agonists. The drug is currently in the clinical trial phase, with studies focusing on its potential use in treating pain, inflammation, and pruritus.
Mechanism of Action[edit | edit source]
CR665 works by binding to and activating the kappa-opioid receptors located in the peripheral nervous system. This action is believed to produce analgesic, anti-inflammatory, and anti-pruritic effects without the central nervous system side effects commonly associated with other opioid drugs.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the safety and efficacy of CR665. These trials have shown promising results, with the drug demonstrating significant pain relief and reduction in inflammation and pruritus in a variety of patient populations.
Potential Uses[edit | edit source]
CR665 has potential uses in a variety of medical conditions. These include chronic pain, osteoarthritis, rheumatoid arthritis, postoperative pain, dermatitis, and other conditions characterized by pain, inflammation, and pruritus.
Side Effects[edit | edit source]
As with all drugs, CR665 has the potential to cause side effects. However, due to its peripheral action, it is expected to have fewer side effects than traditional opioid drugs. The most common side effects reported in clinical trials include nausea, vomiting, and constipation.
Future Developments[edit | edit source]
Cara Therapeutics continues to investigate the potential uses of CR665. Future developments may include further clinical trials and potential approval for use in various medical conditions.
| CR665 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
